In a groundbreaking initiative, David Sinclair, a prominent biologist at Harvard Medical School, is set to launch human trials for a novel “reprogramming” drug aimed at rejuvenating the human body. This experiment will take place as part of a $101 million competition organized by the XPrize Foundation, which challenges teams to demonstrate significant age restoration in participants. Sinclair envisions a future where individuals could obtain prescriptions that effectively make them ten years younger. The objective of this competition is to measure improvements in various health markers, including immune response, cognitive function, and muscle strength, with a grand prize awarded to any team achieving a relative age improvement of ten years or more within a year of treatment. Sinclair’s ambitious research may pave the way for revolutionary advancements in longevity science.
Meanwhile, the ongoing evolution of artificial intelligence (AI) was a hot topic at last week’s SXSW London event, where expert Will Douglas Heaven presented “Five Things You Need to Know About AI.” His discussion highlighted key trends shaping the AI landscape today. Among the points he raised, it was noted that AI technology is now pervasive, permeating various sectors almost simultaneously. However, this rapid integration has sparked concerns about potential misuse and ethical implications, leading to a growing backlash against unchecked AI development. Furthermore, AI’s impact on scientific research is becoming increasingly significant, with its applications revolutionizing everything from data analysis to predictive modeling. As these discussions unfold, it’s clear that understanding AI’s trajectory is essential for navigating its complex implications for society and the economy.
Source: The Download: whole-body rejuvenation drugs and five things to know about AI via MIT Technology Review